Endogenous neuroprotection in chronic neurodegenerative disorders: With particular regard to the kynurenines

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 4, 2011, Pages 701-717

  Zádori, Dénes ^a   Klivényi, Péter ^a   Plangár, Imola ^a   Toldi, József ^b   Vécsei, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Glutamate excitotoxicity; Huntington's disease; Kynurenic acid; Kynurenine pathway; Neurodegeneration; Neuroprotection; Oxidative stress; Parkinson's disease; Quinolinic acid

Indexed keywords

KYNURENINE;

ANIMAL; CELL PROTECTION; CHRONIC DISEASE; DEGENERATIVE DISEASE; HUMAN; METABOLISM; MITOCHONDRION; NERVE CELL; PATHOLOGY; REVIEW;

ANIMALS; CHRONIC DISEASE; CYTOPROTECTION; HUMANS; KYNURENINE; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 79955675748     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01237.x     Document Type: Review

References (256)

1. Parkinson J. An essay on the shaking palsy. London Sherwood, Neely and Jones; 1817.
2. Porter B, Macfarlane R, Unwin N, et al The prevalence of Parkinson's disease in an area of North Tyneside in the North-East of England. Neuroepidemiology. 2006; 26: 156-61.
3. Walker RW, Hand A, Jones C, et al The prevalence of Parkinson's disease in a rural area of North-East England. Parkinsonism Relat Disord. 2010; DOI: .
4. Peters CM, Gartner CE, Silburn PA, et al Prevalence of Parkinson's disease in metropolitan and rural Queensland: a general practice survey. J Clin Neurosci. 2006; 13: 343-8.
5. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5: 525-35.
6. Rodriguez-Oroz MC, Jahanshahi M, Krack P, et al. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009; 8: 1128-39.
7. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003; 24: 197-211.
8. Huntington G. On Chorea. Med Surg Reporter. 1872; 26: 320-1.
9. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993; 72: 971-83.
10. Folstein SE, Chase GA, Wahl WE, et al. Huntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet. 1987; 41: 168-79.
11. Sepcic J, Antonelli L, Sepic-Grahovac D, et al Epidemiology of Huntington's disease in Rijeka district, Yugoslavia. Neuroepidemiology. 1989; 8: 105-8.
12. Evers-Kiebooms G, Nys K, Harper P, et al. Predictive DNA-testing for Huntington's disease and reproductive decision making: a European collaborative study. Eur J Hum Genet. 2002; 10: 167-76.
13. Peterlin B, Kobal J, Teran N, et al. Epidemiology of Huntington's disease in Slovenia. Acta Neurol Scand. 2009; 119: 371-5.
14. Gardian G, Vecsei L. Huntington's disease: pathomechanism and therapeutic perspectives. J Neural Transm. 2004; 111: 1485-94.
15. Walker FO. Huntington's disease. Lancet. 2007; 369: 218-28.
16. Thompson PD, Berardelli A, Rothwell JC, et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain. 1988; 111: 223-44.
17. van Vugt JP, van Hilten BJ, Roos RA. Hypokinesia in Huntington's disease. Mov Disord. 1996; 11: 384-8.
18. Vonsattel JP, Myers RH, Stevens TJ, et al. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985; 44: 559-77.
19. Ferrante RJ, Kowall NW, Beal MF, et al. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 1985; 230: 561-3.
20. Ferrante RJ, Kowall NW, Richardson EP Jr, et al. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neurosci Lett. 1986; 71: 283-8.
21. Reiner A, Albin RL, Anderson KD, et al. Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci USA. 1988; 85: 5733-7.
22. Centonze D, Bernardi G, Koch G. Mechanisms of disease: basic-research-driven investigations in humans - the case of hyperkinetic disorders. Nat Clin Pract Neurol. 2007; 3: 572-80.
23. Sas K, Robotka H, Toldi J, et al Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci. 2007; 257: 221-39.
24. Sas K, Pardutz A, Toldi J, et al. Dementia, stroke and migraine - some common pathological mechanisms. J Neurol Sci. 2010: DOI: .
25. Beckman JS, Beckman TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA. 1990; 87: 1620-4.
26. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993; 262: 689-95.
27. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281: 1309-12.
28. Beal MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 2000; 23: 298-304.
29. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron. 1995; 15: 961-73.
30. Leist M, Single B, Castoldi AF, et al. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med. 1997; 185: 1481-6.
31. Soane L, Kahraman S, Kristian T, et al Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J Neurosci Res. 2007; 85: 3407-15.
32. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997; 91: 479-89.
33. Schrader K, Huai J, Jockel L, et al. Non-caspase proteases: triggers or amplifiers of apoptosis Cell Mol Life Sci. 2010; 67: 1607-18.
34. Langston JW, Ballard P, Tetrud JW, et al Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983; 219: 979-80.
35. Langston JW, Ballard PA Jr. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. N Engl J Med. 1983; 309: 310.
36. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984; 120: 574-8.
37. Langston JW, Irwin I, Langston EB, et al 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neurosci Lett. 1984; 48: 87-92.
38. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. Life Sci. 1985; 36: 2503-8.
39. Mizuno Y, Sone N, Saitoh T. Effects of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain. J Neurochem. 1987; 48: 1787-93.
40. Reichmann H, Riederer P. Biochemical analyses of respiratory chain enzymes in different brain regions of patients with Parkinson's disease. BMFT Symposium "Morbus Parkinson und andere Basalganglienerkrankungen". Bad Kissingen; 1989. p. 44 (abstract).
41. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet. 1989; 1: 1269.
42. Banerjee R, Starkov AA, Beal MF, et al Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta. 2009; 1792: 651-63.
43. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci. 2008; 29: 322-9.
44. Gotz ME, Double K, Gerlach M, et al. The relevance of iron in the pathogenesis of Parkinson's disease. Ann NY Acad Sci. 2004; 1012: 193-208.
45. Lee DW, Andersen JK. Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis J Neurochem. 2010; 112: 332-9.
46. Rivera-Mancia S, Perez-Neri I, Rios C, et al. The transition metals copper and iron in neurodegenerative diseases. Chem Biol Interact. 2010; 186: 184-99.
47. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol. 2008; 7: 97-109.
48. Biskup S, Gerlach M, Kupsch A, et al. Genes associated with Parkinson syndrome. J Neurol. 2008; 255: 8-17.
49. Devi L, Raghavendran V, Prabhu BM, et al. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008; 283: 9089-100.
50. Yang H, Zhou HY, Li B, et al. Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells. J Neuroimmune Pharmacol. 2007; 2: 276-83.
51. Kim Y, Park J, Kim S, et al. PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem Biophys Res Commun. 2008; 377: 975-80.
52. Plun-Favreau H, Klupsch K, Moisoi N, et al. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol. 2007; 9: 1243-52.
53. Andres-Mateos E, Perier C, Zhang L, et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA. 2007; 104: 14807-12.
54. Biskup S, Moore DJ, Celsi F, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006; 60: 557-69.
55. Davidzon G, Greene P, Mancuso M, et al. Early-onset familial parkinsonism due to POLG mutations. Ann Neurol. 2006; 59: 859-62.
56. Stahl WL, Swanson PD. Biochemical abnormalities in Huntington's chorea brains. Neurology. 1974; 24: 813-9.
57. Alston TA, Mela L, Bright HJ. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydrogenase. Proc Natl Acad Sci USA. 1977; 74: 3767-71.
58. He FS, Zhang SL, Liu LH, et al. Extrapyramidal lesions induced by mildewed sugarcane poisoning, three case reports. Chinese J Med. 1987; 67: 395-7.
59. Quastel JH, Wooldridge WR. LXXXIV. Some properties of the dehydrogenating enzymes of bacteria. Biochem J. 1928; 22: 689-702.
60. Gould DH, Gustine DL. Basal ganglia degeneration, myelin alterations, and enzyme inhibition induced in mice by the plant toxin 3-nitropropanoic acid. Neuropathol Appl Neurobiol. 1982; 8: 377-93.
61. Beal MF, Brouillet E, Jenkins B, et al. Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J Neurochem. 1993; 61: 1147-50.
62. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993; 13: 4181-92.
63. Orr AL, Li S, Wang CE, et al. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci. 2008; 28: 2783-92.
64. Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci. 2002; 5: 731-6.
65. Cui L, Jeong H, Borovecki F, et al. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 2006; 127: 59-69.
66. Lucas DR, Newhouse JP. The toxic effect of sodium L-glutamate on the inner layers of the retina. AMA Arch Ophthalmol. 1957; 58: 193-201.
67. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science. 1969; 164: 719-21.
68. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010; 460: 525-42.
69. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002; 5: 405-14.
70. Tovar KR, Westbrook GL. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci. 1999; 19: 4180-8.
71. Liu Y, Wong TP, Aarts M, et al. NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci. 2007; 27: 2846-57.
72. Aramori I, Nakanishi S. Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells. Neuron. 1992; 8: 757-65.
73. Abe T, Sugihara H, Nawa H, et al. Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem. 1992; 267: 13361-8.
74. Tanabe Y, Nomura A, Masu M, et al. Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4. J Neurosci. 1993; 13: 1372-8.
75. Schousboe A, Waagepetersen HS. Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res. 2005; 8: 221-5.
76. Novelli A, Reilly JA, Lysko PG, et al Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res. 1988; 451: 205-12.
77. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003; 4: 552-65.
78. Meredith GE, Totterdell S, Beales M, et al Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease. Exp Neurol. 2009; 219: 334-40.
79. Caudle WM, Zhang J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol. 2009; 220: 230-3.
80. Misgeld U. Innervation of the substantia nigra. Cell Tissue Res. 2004; 318: 107-14.
81. Rodriguez MC, Obeso JA, Olanow CW. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol. 1998; 44: S175-88.
82. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature. 1976; 263: 244-6.
83. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature. 1976; 263: 517-9.
84. Schwarcz R, Hokfelt T, Fuxe K, et al. Ibotenic acid-induced neuronal degeneration: a morphological and neurochemical study. Exp Brain Res. 1979; 37: 199-216.
85. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983; 219: 316-8.
86. Beal MF, Kowall NW, Ellison DW, et al. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986; 321: 168-71.
87. Fonnum F, Storm-Mathisen J, Divac I. Biochemical evidence for glutamate as neurotransmitter in corticostriatal and corticothalamic fibres in rat brain. Neuroscience. 1981; 6: 863-73.
88. Smith Y, Raju DV, Pare JF, et al The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci. 2004; 27: 520-7.
89. Landwehrmeyer GB, Standaert DG, Testa CM, et al. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci. 1995; 15: 5297-307.
90. Zeron MM, Hansson O, Chen N, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron. 2002; 33: 849-60.
91. Shehadeh J, Fernandes HB, Zeron Mullins MM, et al. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2006; 21: 392-403.
92. Young AB, Greenamyre JT, Hollingsworth Z, et al. NMDA receptor losses in putamen from patients with Huntington's disease. Science. 1988; 241: 981-3.
93. Kuppenbender KD, Standaert DG, Feuerstein TJ, et al. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J Comp Neurol. 2000; 419: 407-21.
94. Milnerwood AJ, Gladding CM, Pouladi MA, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 2010; 65: 178-90.
95. Okamoto S, Pouladi MA, Talantova M, et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 2009; 15: 1407-13.
96. Chen N, Luo T, Wellington C, et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem. 1999; 72: 1890-8.
97. Song C, Zhang Y, Parsons CG, et al Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors. J Biol Chem. 2003; 278: 33364-9.
98. Heng MY, Detloff PJ, Wang PL, et al. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci. 2009; 29: 3200-5.
99. Sun Y, Savanenin A, Reddy PH, et al Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J Biol Chem. 2001; 276: 24713-8.
100. Sattler R, Xiong Z, Lu WY, et al. Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science. 1999; 284: 1845-8.
101. Hassel B, Tessler S, Faull RL, et al Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res. 2008; 33: 232-7.
102. Cha JH, Kosinski CM, Kerner JA, et al. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci USA. 1998; 95: 6480-5.
103. Tang TS, Tu H, Chan EY, et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron. 2003; 39: 227-39.
104. Kotake Y, Iwao J. Über das Kynurenin, ein intermediäres Stoffwechselprodukt des Tryptophans. Z Physiol Chem. 1931; 195: 139-47.
105. Matsuoka Z, Yoshimatsu N. Über eine neue Substanz, die aus Tryptophan im Tierkörper gebildet wird. Z Physiol Chem. 1925; 143: 206-10.
106. Wolf H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand J Clin Lab Invest Suppl. 1974; 136: 1-186.
107. Beadle GW, Mitchell HK, Nyc JF. Kynurenine as an Intermediate in the Formation of Nicotinic Acid from Tryptophane by Neurospora. Proc Natl Acad Sci USA. 1947; 33: 155-8.
108. Liebig J. Ueber Kynurensäure. Justus Liebigs Ann Chem. 1853; 86: 125-6.
109. Jackson RW, Jackson WT. The metabolism of tryptophan III. The availability of kynurenine in supplementing a diet deficient in tryptophane. J Biol Chem. 1932; 96: 697-701.
110. Kotake Y, Nakayama Y. Studien über den intermediären Stoffwechsel des Tryptophans. XXXIV. Über die Anthranilsäurebildung aus Kynurenin durch Organsaft. Z Physiol Chem. 1941; 270: 76-82.
111. +-Gen-abhängiges Glied im intermediären Tryptophan-Stoffwechsel. Z Naturf. 1949; 4b: 242-4.
112. Henderson LM. Quinolinic acid excretion by the rat receiving tryptophan. J Biol Chem. 1949; 178: 1005-6.
113. Henderson LM, Hirsch HM. Quinolinic acid metabolism; urinary excretion by the rat following tryptophan and 3-hydroxyanthranilic acid administration. J Biol Chem. 1949; 181: 667-75.
114. Joseph MH. The determination of kynurenine by gas-liquid chromatography; evidence for its presence in rat brain [proceedings]. Br J Pharmacol. 1977; 59: 525P.
115. Gal EM, Sherman AD. Synthesis and metabolism of L-kynurenine in rat brain. J Neurochem. 1978; 30: 607-13.
116. Joseph MH, Kadam BV. Kynurenine: penetration to the brain, effect on brain tryptophan and 5-hydroxytryptamine metabolism and binding to plasma albumin [proceedings]. Br J Pharmacol. 1979; 66: 483P-4P.
117. Gould SE. The uptake of kynurenine, a tryptophan metabolite, into mouse brain [proceedings]. Br J Pharmacol. 1979; 66: 484P-5P.
118. Fukui S, Schwarcz R, Rapoport SI, et al. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991; 56: 2007-17.
119. Lombardi G, Moneti G, Moroni F. Mass-fragmentographic identification and measurement of the excitotoxin quinolinic acid in the mammalian brain. Acta Pharmacol Toxicol. 1983; 53: 145.
120. Zadori D, Klivenyi P, Vamos E, et al. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm. 2009; 116: 1403-9.
121. Kincses ZT, Toldi J, Vecsei L. Kynurenines, neurodegeneration and Alzheimer's disease. J Cell Mol Med. 2010; DOI: .
122. Rajda C, Bergquist J, Vecsei L. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis. J Neural Transm Suppl. 2007; 72: 323-9.
123. Lapin IP. Kynurenines as probable participants of depression. Pharmakopsychiatr Neuropsychopharmakol. 1973; 6: 273-9.
124. Lapin IP. Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. J Neural Transm. 1978; 42: 37-43.
125. Han Q, Cai T, Tagle DA, et al Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci. 2010; 67: 353-68.
126. Okuno E, Nakamura M, Schwarcz R. Two kynurenine aminotransferases in human brain. Brain Res. 1991; 542: 307-12.
127. Yu P, Li Z, Zhang L, et al. Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene. 2006; 365: 111-8.
128. Guidetti P, Amori L, Sapko MT, et al. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem. 2007; 102: 103-11.
129. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001; 78: 842-53.
130. Roberts RC, Du F, McCarthy KE, et al. Immunocytochemical localization of kynurenine aminotransferase in the rat striatum: a light and electron microscopic study. J Comp Neurol. 1992; 326: 82-90.
131. Guidetti P, Hoffman GE, Melendez-Ferro M, et al. Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia. 2007; 55: 78-92.
132. Battie C, Verity MA. Presence of kynurenine hydroxylase in developing rat brain. J Neurochem. 1981; 36: 1308-10.
133. Foster AC, White RJ, Schwarcz R. Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J Neurochem. 1986; 47: 23-30.
134. Espey MG, Chernyshev ON, Reinhard JF Jr, et al. Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport. 1997; 8: 431-4.
135. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982; 247: 184-7.
136. Kessler M, Terramani T, Lynch G, et al A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989; 52: 1319-28.
137. Birch PJ, Grossman CJ, Hayes AG. Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors. Eur J Pharmacol. 1988; 151: 313-5.
138. Prescott C, Weeks AM, Staley KJ, et al Kynurenic acid has a dual action on AMPA receptor responses. Neurosci Lett. 2006; 402: 108-12.
139. Rozsa E, Robotka H, Vecsei L, et al The Janus-face kynurenic acid. J Neural Transm. 2008; 115: 1087-91.
140. Hilmas C, Pereira EF, Alkondon M, et al. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001; 21: 7463-73.
141. Marchi M, Risso F, Viola C, et al. Direct evidence that release-stimulating alpha7* nicotinic cholinergic receptors are localized on human and rat brain glutamatergic axon terminals. J Neurochem. 2002; 80: 1071-8.
142. Wang J, Simonavicius N, Wu X, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem. 2006; 281: 22021-8.
143. Csillik AE, Okuno E, Csillik B, et al. Expression of kynurenine aminotransferase in the subplate of the rat and its possible role in the regulation of programmed cell death. Cereb Cortex. 2002; 12: 1193-201.
144. de Carvalho LP, Bochet P, Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int. 1996; 28: 445-52.
145. Stone TW, Perkins MN. Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol. 1981; 72: 411-2.
146. Connick JH, Stone TW. Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol. 1988; 93: 868-76.
147. Tavares RG, Tasca CI, Santos CE, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int. 2002; 40: 621-7.
148. Behan WM, McDonald M, Darlington LG, et al Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol. 1999; 128: 1754-60.
149. Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res. 1991; 16: 1139-43.
150. Eastman CL, Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res. 1990; 15: 1101-7.
151. Okuda S, Nishiyama N, Saito H, et al 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998; 70: 299-307.
152. Dykens JA, Sullivan SG, Stern A. Oxidative reactivity of the tryptophan metabolites 3-hydroxyanthranilate, cinnabarinate, quinolinate and picolinate. Biochem Pharmacol. 1987; 36: 211-7.
153. Jhamandas K, Boegman RJ, Beninger RJ, et al Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res. 1990; 529: 185-91.
154. Ogawa T, Matson WR, Beal MF, et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology. 1992; 42: 1702-6.
155. Knyihar-Csillik E, Csillik B, Pakaski M, et al. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treatment. Neuroscience. 2004; 126: 899-914.
156. Knyihar-Csillik E, Chadaide Z, Mihaly A, et al. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol. 2006; 112: 127-37.
157. Luchowski P, Luchowska E, Turski WA, et al 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci Lett. 2002; 330: 49-52.
158. Beal MF, Matson WR, Swartz KJ, et al. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem. 1990; 55: 1327-39.
159. Jauch D, Urbanska EM, Guidetti P, et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci. 1995; 130: 39-47.
160. Guidetti P, Luthi-Carter RE, Augood SJ, et al Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis. 2004; 17: 455-61.
161. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992; 115: 1249-73.
162. Schwarcz R, Okuno E, White RJ, et al. 3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims. Proc Natl Acad Sci USA. 1988; 85: 4079-81.
163. Vecsei L, Beal MF. Comparative behavioral and neurochemical studies with striatal kainic acid- or quinolinic acid-lesioned rats. Pharmacol Biochem Behav. 1991; 39: 473-8.
164. Schwarcz R, Guidetti P, Sathyasaikumar KV, et al Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol. 2010; 90: 230-45.
165. Sapko MT, Guidetti P, Yu P, et al. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol. 2006; 197: 31-40.
166. Pearson SJ, Reynolds GP. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci Lett. 1992; 144: 199-201.
167. Guidetti P, Schwarcz R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur J Neurosci. 1999; 11: 3857-63.
168. Csillik A, Knyihar E, Okuno E, et al. Effect of 3-nitropropionic acid on kynurenine aminotransferase in the rat brain. Exp Neurol. 2002; 177: 233-41.
169. Giorgini F, Guidetti P, Nguyen Q, et al. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet. 2005; 37: 526-31.
170. Hersch SM, Rosas HD. Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics. 2008; 5: 226-36.
171. Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. Eur J Clin Pharmacol. 2010; 66: 119-25.
172. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010; 90: 905-81.
173. Kincses ZT, Vecsei L. Pharmacological therapy in Parkinson's disease: focus on neuroprotection. CNS Neurosci Ther. 2010; DOI: .
174. Liu J, Atamna H, Kuratsune H, et al Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann NY Acad Sci. 2002; 959: 133-66.
175. Wang C, Sadovova N, Ali HK, et al. L-carnitine protects neurons from 1-methyl-4-phenylpyridinium-induced neuronal apoptosis in rat forebrain culture. Neuroscience. 2007; 144: 46-55.
176. Bodis-Wollner I, Chung E, Ghilardi MF, et al. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J Neural Transm Park Dis Dement Sect. 1991; 3: 63-72.
177. Zhang H, Jia H, Liu J, et al. Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. J Cell Mol Med. 2010; 14: 215-25.
178. Nishimura M, Okimura Y, Fujita H, et al. Mechanism of 3-nitropropionic acid-induced membrane permeability transition of isolated mitochondria and its suppression by L-carnitine. Cell Biochem Funct. 2008; 26: 881-91.
179. Vamos E, Voros K, Vecsei L, et al Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomed Pharmacother. 2010; 64: 282-6.
180. Goetz CG, Tanner CM, Cohen JA, et al. L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia. Mov Disord. 1990; 5: 263-5.
181. Boldyrev AA, Stvolinsky SL, Fedorova TN, et al Carnosine as a natural antioxidant and geroprotector: from molecular mechanisms to clinical trials. Rejuvenation Res. 2010; 13: 156-8.
182. Boldyrev A, Fedorova T, Stepanova M, et al. Carnosine increases efficiency of DOPA therapy of Parkinson's disease: a pilot study. Rejuvenation Res. 2008; 11: 821-7.
183. 10 attenuates the 1-methyl-4-phenyl-1, 2, 3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998; 783: 109-14.
184. 10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model. Neurosci Lett. 2001; 315: 149-53.
185. 10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci. 2002; 22: 1592-9.
186. Strijks E, Kremer HP, Horstink MW. Q10 therapy in patients with idiopathic Parkinson's disease. Mol Aspects Med. 1997; 18: S237-40.
187. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002; 59: 1541-50.
188. Muller T, Buttner T, Gholipour AF, et al Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003; 341: 201-4.
189. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007; 64: 938-44.
190. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology. 2001; 57: 397-404.
191. The Huntington Study Group Pre2CARE Investigators. Safety and tolerability of high-dosage coenzyme Q(10) in Huntington's disease and healthy subjects. Mov Disord. 2010; 25: 1924-8.
192. Hemmer W, Wallimann T. Functional aspects of creatine kinase in brain. Dev Neurosci. 1993; 15: 249-60.
193. O'Gorman E, Beutner G, Dolder M, et al. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 1997; 414: 253-7.
194. Matthews RT, Ferrante RJ, Klivenyi P, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999; 157: 142-9.
195. Matthews RT, Yang L, Jenkins BG, et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci. 1998; 18: 156-63.
196. Ferrante RJ, Andreassen OA, Jenkins BG, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000; 20: 4389-97.
197. Andreassen OA, Dedeoglu A, Ferrante RJ, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol Dis. 2001; 8: 479-91.
198. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006; 66: 664-71.
199. NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008; 31: 141-50.
200. Bender A, Koch W, Elstner M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006; 67: 1262-4.
201. Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology. 2003; 61: 141-2.
202. Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology. 2005; 64: 1655-6.
203. Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology. 2003; 61: 925-30.
204. Kessler A, Biasibetti M, da Silva Melo DA, et al. Antioxidant effect of cysteamine in brain cortex of young rats. Neurochem Res. 2008; 33: 737-44.
205. Rech VC, Feksa LR, Fleck RM, et al. Cysteamine prevents inhibition of thiol-containing enzymes caused by cystine or cystine dimethylester loading in rat brain cortex. Metab Brain Dis. 2008; 23: 133-45.
206. Karpuj MV, Becher MW, Steinman L. Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications. Neurochem Int. 2002; 40: 31-6.
207. Martinovits G, Melamed E, Cohen O, et al. Systemic administration of antioxidants does not protect mice against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine (MPTP). Neurosci Lett. 1986; 69: 192-7.
208. Sun L, Xu S, Zhou M, et al. Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Brain Res. 2010; 1335: 74-82.
209. Tremblay ME, Saint-Pierre M, Bourhis E, et al. Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging. 2006; 27: 862-70.
210. Karpuj MV, Becher MW, Springer JE, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med. 2002; 8: 143-9.
211. Dedeoglu A, Kubilus JK, Jeitner TM, et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci. 2002; 22: 8942-50.
212. Van Raamsdonk JM, Pearson J, Bailey CD, et al. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem. 2005; 95: 210-20.
213. Dubinsky R, Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord. 2006; 21: 530-3.
214. Jump DB. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem. 2002; 277: 8755-8.
215. Vaddadi KS. Essential fatty acids and movement disorders. In: Peet M, Glen I, Horrobin DF, editors. Phospholipid spectrum disorders in psychiatry. Carnforth Marius Press; 1999. pp. 285-96.
216. Clifford JJ, Drago J, Natoli AL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience. 2002; 109: 81-8.
217. Vaddadi KS, Soosai E, Chiu E, et al A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport. 2002; 13: 29-33.
218. Van Raamsdonk JM, Pearson J, Rogers DA, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005; 196: 266-72.
219. Puri BK, Bydder GM, Counsell SJ, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport. 2002; 13: 123-6.
220. Puri BK, Bydder GM, Manku MS, et al. Reduction in cerebral atrophy associated with ethyl-eicosapentaenoic acid treatment in patients with Huntington's disease. J Int Med Res. 2008; 36: 896-905.
221. Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology. 2005; 65: 286-92.
222. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008; 65: 1582-9.
223. Andreassen OA, Ferrante RJ, Dedeoglu A, et al Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport. 2001; 12: 3371-3.
224. Mazzio E, Soliman KF. Pyruvic acid cytoprotection against 1-methyl-4-phenylpyridinium, 6-hydroxydopamine and hydrogen peroxide toxicities in vitro. Neurosci Lett. 2003; 337: 77-80.
225. Choi JS, Lee MS, Jeong JW. Ethyl pyruvate has a neuroprotective effect through activation of extracellular signal-regulated kinase in Parkinson's disease model. Biochem Biophys Res Commun. 2010; 394: 854-8.
226. Ryu JK, Kim SU, McLarnon JG. Neuroprotective effects of pyruvate in the quinolinic acid rat model of Huntington's disease. Exp Neurol. 2003; 183: 700-4.
227. Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids. 2009; 37: 1-17.
228. Tadros MG, Khalifa AE, Abdel-Naim AB, et al Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. Pharmacol Biochem Behav. 2005; 82: 574-82.
229. Perry TL, Yong VW, Hansen S, et al. Alpha-tocopherol and beta-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. J Neurol Sci. 1987; 81: 321-31.
230. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993; 328: 176-83.
231. Cadet JL, Katz M, Jackson-Lewis V, et al Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 1989; 476: 10-5.
232. Bostanci MO, Bas O, Bagirici F. Alpha-tocopherol decreases iron-induced hippocampal and nigral neuron loss. Cell Mol Neurobiol. 2010; 30: 389-94.
233. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann Neurol. 1992; 32: S128-32.
234. Peyser CE, Folstein M, Chase GA, et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry. 1995; 152: 1771-5.
235. Itoh N, Masuo Y, Yoshida Y, et al. gamma-Tocopherol attenuates MPTP-induced dopamine loss more efficiently than alpha-tocopherol in mouse brain. Neurosci Lett. 2006; 403: 136-40.
236. Miranda AF, Boegman RJ, Beninger RJ, et al Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid. Neuroscience. 1997; 78: 967-75.
237. Harris CA, Miranda AF, Tanguay JJ, et al. Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid. Br J Pharmacol. 1998; 124: 391-9.
238. Nozaki K, Beal MF. Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats. J Cereb Blood Flow Metab. 1992; 12: 400-7.
239. Gigler G, Szenasi G, Simo A, et al. Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils. Eur J Pharmacol. 2007; 564: 116-22.
240. Knyihar-Csillik E, Toldi J, Mihaly A, et al. Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. J Neural Transm. 2007; 114: 417-21.
241. Vamos E, Pardutz A, Fejes A, et al. Modulatory effects of probenecid on the nitroglycerin-induced changes in the rat caudal trigeminal nucleus. Eur J Pharmacol. 2009; 621: 33-7.
242. Vamos E, Voros K, Zadori D, et al. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. J Neural Transm. 2009; 116: 1079-86.
243. Graham WC, Robertson RG, Sambrook MA, et al Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sci. 1990; 47: PL91-7.
244. Butler EG, Bourke DW, Finkelstein DI, et al The effects of reversible inactivation of the subthalamo-pallidal pathway on the behaviour of naive and hemiparkinsonian monkeys. J Clin Neurosci. 1997; 4: 218-27.
245. Bahn A, Ljubojevic M, Lorenz H, et al. Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005; 289: C1075-84.
246. Stone TW. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci. 2000; 21: 149-54.
247. Schwarcz R. The kynurenine pathway of tryptophan degradation as a drug target. Curr Opin Pharmacol. 2004; 4: 12-7.
248. Fulop F, Szatmari I, Vamos E, et al. Syntheses, transformations and pharmaceutical applications of kynurenic acid derivatives. Curr Med Chem. 2009; 16: 4828-42.
249. Merino M, Vizuete ML, Cano J, et al The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2, 3-dione and 2, 3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+. J Neurochem. 1999; 73: 750-7.
250. Guidetti P, Wu HQ, Schwarcz R. In situ produced 7-chlorokynurenate provides protection against quinolinate-and malonate-induced neurotoxicity in the rat striatum. Exp Neurol. 2000; 163: 123-30.
251. Parli CJ, Krieter P, Schmidt B. Metabolism of 6-chlorotryptophan to 4-chloro-3-hydroxyanthranilic acid: a potent inhibitor of 3-hydroxyanthranilic acid oxidase. Arch Biochem Biophys. 1980; 203: 161-6.
252. Leeson PD, Baker R, Carling RW, et al. Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor. J Med Chem. 1991; 34: 1243-52.
253. Borza I, Kolok S, Galgoczy K, et al. Kynurenic acid amides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett. 2007; 17: 406-9.
254. Vamos E, Fejes A, Koch J, et al. Kynurenate derivative attenuates the nitroglycerin-induced CamKIIalpha and CGRP expression changes. Headache. 2010; 50: 834-43.
255. Marosi M, Nagy D, Farkas T, et al. A novel kynurenic acid analogue: a comparison with kynurenic acid. An in vitro electrophysiological study. J Neural Transm. 2010; 117: 183-8.
256. Zadori D, Nyiri G, Szonyi A, et al. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm. 2011; DOI: .